药明康德获2024年EcoVadis企业社会包袱评级“金牌”认证｜Bilingual News

转自：药明康德

▎药明康德

上海，2024年11月21日 – 药明康德近日文书，公司在2024年EcoVadis企业社会包袱评级中获取金牌认证，位列总共参评公司前2%。这一评级不仅彰显了药明康德对可握续发展的强硬得意，也体现了公司将环境及社会包袱融入政策有想象和业务运营的不懈奋发。

EcoVadis当作民众驰名的企业社会包袱和可握续发展评估平台，是民众企业量度和升迁业务和价值链可握续发展施展的弥留参考目的。在这次评估中，药明康德获取了80分（满分100分），响应了公司在环境、服务与东谈主权、谈德和可握续采购四大中枢ESG界限中的施展稳步升迁。

“荣获EcoVadis金牌认证进一步确定了药明康德在价值链可握续发展中的超卓实施和绩效施展，”药明康德副董事长兼ESG委员会主席胡正国先生示意，“咱们将永恒接力于在公司运营的各个方面鼓舞可握续发展，也很自傲能助力客户推动更多改进疗法早日问世，造福民众病患，不断为医药健康行业带来握久而积极的影响。”

当作改进的赋能者、客户相信的配结伴伴以及民众健康产业的孝顺者，药明康德将ESG理念融入公司政策和运营的方方面面。2024年，药明康德在标普民众企业可握续发展评估（S&P Global Corporate Sustainability Assessment，CSA）中获取行业最高分，位列民众“生命科学用具与服务”界限第一；同庚，药明康德谐和第四年被MSCI评为ESG AA级；2023和2024年，公司谐和两年入选标普民众可握续发展年鉴和富时罗素社会包袱指数系列，并同期获评Sustainalytics“行业最高评级”和“区域最高评级”企业；2024年，公司加入了“谐和国民众条约组织”（United Nations Global Compact，UNGC），得意救援民众条约十项原则；2023年，公司加入“科学碳标的倡议”（Science Based Targets initiative，SBTi）以减少碳排放。药明康德出色的ESG施展也受到了CDP、ISS等民众ESG评级机构的高度招供。

对于药明康德

药明康德（股票代码：603259.SH/2359.HK）为民众医药及生命科学行业提供一体化、端到端的新药研发和坐蓐服务，在亚洲、欧洲、北好意思等地均设有运营基地。药明康德通过独到的“CRDMO”和“CTDMO”业务方式，不断缩小研发门槛，助力客户升迁研发后果，为患者带来更多冲突性的颐养决策，服务范围涵盖化学药研发和坐蓐、生物学臆想、临床前测试和临床进修研发、精确医疗研发、测试和坐蓐等界限。2024年，药明康德谐和第四年被MSCI评为ESG（环境、社会及管治）AA级。当今，公司的赋能平台正承载着来自民众30多个国度的6,000多家配结伴伴的研发改进技俩，接力于将更多新药、好药带给民众病患，早日兑现“让宇宙莫得难作念的药，难治的病”的愿景。

WuXi AppTec Receives Gold Medal in 2024 EcoVadis Sustainability Rating

Shanghai, November 20, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, announced that it has been awarded a gold medal in the 2024 EcoVadis business sustainability rating, ranking in the top 2% of all participating companies. This achievement reflects WuXi AppTec’s commitment to sustainability and its ongoing efforts to integrate environmental and social responsibilities into the company’s business strategies and operations.

EcoVadis is a leading ratings organization in supply chain sustainability, serving as a crucial benchmark for companies of all sizes worldwide to enhance their long-term sustainability performance in business and value chains. WuXi AppTec’s EcoVadis score of 80 out of 100 points reflects steady improvements in the four key ESG categories: environment, labor & human rights, ethics, and sustainable procurement.

“Receiving the EcoVadis Gold Medal is a reflection of the strong progress we have made implementing sustainable development and strong ESG practices throughout our entire value chain,” said Edward Hu, Vice Chairman of WuXi AppTec and Chairman of WuXi AppTec’s ESG Committee. “We remain dedicated to advancing sustainability efforts in every aspect of our operations. We are proud to support our customers in delivering innovative new therapies to patients and make a lasting, positive impact on the healthcare industry as a whole.”

As an enabler of innovation, a trusted partner, and a contributor to the global pharmaceutical and life sciences industry, WuXi AppTec integrates ESG priorities in all aspects of its global business operations. In 2024, WuXi AppTec ranked #1 in the Global Life Sciences Tools & Services Industry in S&P Global’s Corporate Sustainability Assessment and received an AA ESG rating from MSCI for the fourth consecutive year. The company was also named to the S&P Global Sustainability Yearbook and the FTSE4Good Index Series in both 2023 and 2024, and was recognized as an Industry and Regional “Top-Rated” company by Sustainalytics. WuXi AppTec’s outstanding ESG performance has been widely acknowledged by major global ESG rating agencies, including CDP and ISS.

In addition, WuXi AppTec participates in global efforts to advance sustainability. For example, WuXi AppTec joined the United Nations Global Compact (UNGC) in 2024 to support its ten sustainability principles. In 2023, WuXi AppTec joined the Science Based Targets initiative (SBTi) to reduce carbon emissions.

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development, and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the fourth consecutive year in 2024, and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated."

（转自：药明康德）